-
Calls Purchased on Nektar Therapeutics (NKTR)
Friday, June 11, 2010 - 10:57am | 153Shares of Nektar Therapeutics (NASDAQ: NKTR) are higher on the session, currently trading at $12.98. The stock has been drifting lower for the past three months, but the stock has found support at the 200-day moving average. It is now nearing the 50-day moving average from the downside. Options...
-
Benzinga’s Top Pre-Market Gainers (ARST, XIDE, SQNM, ARMH)
Friday, June 11, 2010 - 8:35am | 190Arc Sight Inc (NASDAQ: ARST) soared 12.01% to $22.2 in the pre-market session. Yesterday, the security and compliance management software provider announced quarterly revenue growth of 41% year-over-year for fiscal Q4 ended April 30, beating Wall Street estimates. Exide Technologies (NASDAQ: XIDE)...
-
Benzinga’s Volume Movers (MDAS, NKTR, TCAP, EQIX)
Wednesday, June 9, 2010 - 1:53pm | 170MedAssets Inc (NASDAQ: MDAS) shares jumped 2.47% to $24.05 at 11:47 am. The volume of MDAS shares traded was 557% higher than normal. MDAS has renewed a long-term spend management agreement with University of Pittsburgh Medical Center. Nektar Therapeutics (NASDAQ: NKTR) shares climbed 6.58% to $11....
-
Hapoalim Reiterates Buy Rating for Nektar Therapeutics
Tuesday, June 8, 2010 - 8:27am | 123Hapoalim Securities healthcare analyst Jon LeCroy maintains his Buy rating for shares of Nektar Therapeutics (NASDAQ: NKTR). Nektar's new cancer drug NKTR-102 is in trials right now, with results expected in mid-2010. "Dr. Verschraegen, who discussed the data, stated that the results were at the...
-
Puts Purchased on Covance (CVD)
Monday, June 7, 2010 - 10:51am | 128Shares of Covance Inc. (NYSE: CVD) are lower on the session by 0.90%, currently trading $51.58. The stock has been falling for the past four weeks and is now trading below both the 50-day and 200-day moving average. Options traders are betting that the name slides further as well. The June $50 put...
-
Thermo Fisher Scientific to Present at the Jefferies 2010 Global Life Sciences Conference (TMO)
Friday, June 4, 2010 - 4:04pm | 281Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Pete Wilver, senior vice president and chief financial officer, will present at the Jefferies 2010 Global Life Sciences Conference being held at the Grand Hyatt New York, NY. The presentation will take...
-
Puts Sold on Thermo Fisher (TMO)
Friday, June 4, 2010 - 1:08pm | 111Shares of Thermo Fisher Scientific Inc. (NYSE: TMO) are lower on the session by 3.63%, currently trading $50.23. The stock has been struggling as of late, but the stock is currently trading above the 200-day moving average. Puts are being sold on the name today with the June $50 put sold 3,200...
-
Sellers Packed Up Their Tents 06-03-2010
Thursday, June 3, 2010 - 6:48pm | 725Cusick’s Corner While the market challenges long-term resistance, 200-Day Moving Average SPX 1105.5, traders are waiting for tomorrow’s Unemployment number which is estimated at 500K. This rally is in the face of a declining Euro and bullish EU market, a potential indicator that the sellers have...
-
Calls Bought on Exelixis (EXEL)
Thursday, June 3, 2010 - 1:45pm | 124Shares of Exelixis (NASDAQ: EXEL) are higher on the session by 6.47%, currently trading $5.43. The stock is popping today after the company said they were going to raise $160 million to repay obligations under a loan from GlaxoSmithKline. Options traders are coming after calls in the name with the...
-
PRXL Introduces FY2011 Guidance In Line With Expectations
Thursday, June 3, 2010 - 11:15am | 137Analysts at William Blair & Co maintain their "market perform" rating on Parexel International Corporation (NASDAQ: PRXL). PRXL has updated its fiscal 2010 guidance expectations, along with introducing fiscal 2011 guidance, in line with the estimates and the consensus. “It appears that both our...
-
Jefferies Lowers Estimates and Price Target on Parexel (PRXL)
Thursday, June 3, 2010 - 11:04am | 213Jefferies is out with an analyst note this morning that lowers estimates and the price target for Parexel International (NASDAQ: PRXL), though maintains the Buy rating on the stock. Jefferies has a $28.00 price target; down from $29.00. Analysts cited the company recently updating their FY11...
-
Puts Sold on Illumina (ILMN)
Wednesday, June 2, 2010 - 12:58pm | 111Shares of Illumina Inc. (NASDAQ: ILMN) are higher on the session by 2.15%, currently trading $42.38. The stock has been a relative outperformer as of late and has managed to hold the 50-day moving average as well. The stock is nearing its 52-week high. Puts are being sold on the name today with...
-
Clarity In TMO’s Capital Re-Deployment Should Increase Investor Appeal
Friday, May 28, 2010 - 11:25am | 203Analysts at Jefferies & Co reiterate their "buy" rating on Thermo Fisher Scientific (NYSE: TMO), while reducing their estimates for the company. The target price for TMO is set to $63. According to the analysts, TMO's initial 2011 “core operating outlook along with longer-term base operating...
-
JP Morgan Maintains Overweight Rating On Thermo Fisher Scientific, Inc. (TMO)
Thursday, May 27, 2010 - 1:43pm | 95Analysts at JP Morgan have released an update on Thermo Fisher Scientific, Inc. (NYSE: TMO). The company hosted its analyst meeting in New York City. The meeting touched on familiar themes including growth drivers for both divisions, benefits from cost containment initiatives, plans for expansion...
-
Update on Xenoport's Horizant - Analyst Blog
Thursday, May 27, 2010 - 1:06pm | 508The US Food and Drug Administration (FDA) has asked for additional pre-clinical data on XP13512 (known as Horizant (gabapentin enacarbil) in the US), co-developed by XenoPort (XNPT) and GlaxoSmithKline (GSK) for the treatment of primary restless legs syndrome (RLS). Although a New Drug Application...